284 related articles for article (PubMed ID: 34750611)
1. Clinical and pathological analysis of companion diagnostic testing of microsatellite instability-high for pembrolizumab in gynaecologic malignancy.
Takeda T; Tsuji K; Kobayashi Y; Banno K; Aoki D
Jpn J Clin Oncol; 2022 Feb; 52(2):128-133. PubMed ID: 34750611
[TBL] [Abstract][Full Text] [Related]
2. Tumor site discordance in mismatch repair deficiency in synchronous endometrial and ovarian cancers.
Kim SR; Tone A; Kim R; Cesari M; Clarke B; Eiriksson L; Hart T; Aronson M; Holter S; Lytwyn A; Maganti M; Oldfield L; Gallinger S; Bernardini MQ; Oza AM; Djordjevic B; Lerner-Ellis J; Van de Laar E; Vicus D; Pugh TJ; Pollett A; Ferguson SE
Int J Gynecol Cancer; 2020 Dec; 30(12):1951-1958. PubMed ID: 33082239
[TBL] [Abstract][Full Text] [Related]
3. A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability.
Bellone S; Roque DM; Siegel ER; Buza N; Hui P; Bonazzoli E; Guglielmi A; Zammataro L; Nagarkatti N; Zaidi S; Lee J; Silasi DA; Huang GS; Andikyan V; Damast S; Clark M; Azodi M; Schwartz PE; Tymon-Rosario JR; Harold JA; Mauricio D; Zeybek B; Menderes G; Altwerger G; Ratner E; Alexandrov LB; Iwasaki A; Kong Y; Song E; Dong W; Elvin JA; Choi J; Santin AD
Cancer; 2022 Mar; 128(6):1206-1218. PubMed ID: 34875107
[TBL] [Abstract][Full Text] [Related]
4. A Durable Response to Pembrolizumab in a Patient with Uterine Serous Carcinoma and Lynch Syndrome due to the MSH6 Germline Mutation.
T Danley K; Schmitz K; Ghai R; Sclamberg JS; Buckingham LE; Burgess K; Kuzel TM; Usha L
Oncologist; 2021 Oct; 26(10):811-817. PubMed ID: 34018286
[TBL] [Abstract][Full Text] [Related]
5. Universal endometrial cancer tumor typing: How much has immunohistochemistry, microsatellite instability, and MLH1 methylation improved the diagnosis of Lynch syndrome across the population?
Kahn RM; Gordhandas S; Maddy BP; Baltich Nelson B; Askin G; Christos PJ; Caputo TA; Chapman-Davis E; Holcomb K; Frey MK
Cancer; 2019 Sep; 125(18):3172-3183. PubMed ID: 31150123
[TBL] [Abstract][Full Text] [Related]
6. Microsatellite instability analysis for the screening of synchronous endometrial and ovarian cancer in Lynch syndrome.
Bats AS; Roussel H; Narjoz C; Le Frere-Belda MA; Chamming's F; Blons H; Laurent-Puig P; Lecuru F
Anticancer Res; 2013 Sep; 33(9):3977-81. PubMed ID: 24023337
[TBL] [Abstract][Full Text] [Related]
7. A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793).
Bellone S; Roque DM; Siegel ER; Buza N; Hui P; Bonazzoli E; Guglielmi A; Zammataro L; Nagarkatti N; Zaidi S; Lee J; Silasi DA; Huang GS; Andikyan V; Damast S; Clark M; Azodi M; Schwartz PE; Tymon-Rosario J; Harold J; Mauricio D; Zeybek B; Menderes G; Altwerger G; Ratner E; Alexandrov LB; Iwasaki A; Kong Y; Song E; Dong W; Elvin J; Choi J; Santin AD
Ann Oncol; 2021 Aug; 32(8):1045-1046. PubMed ID: 33932502
[No Abstract] [Full Text] [Related]
8. Prevalence of Lynch syndrome among patients with upper urinary tract carcinoma in a Japanese hospital-based population.
Ito T; Kono K; Eguchi H; Okazaki Y; Yamamoto G; Tachikawa T; Akagi K; Okada Y; Kawakami S; Morozumi M; Tamaru JI; Ishida H
Jpn J Clin Oncol; 2020 Jan; 50(1):80-88. PubMed ID: 31665498
[TBL] [Abstract][Full Text] [Related]
9. The proportion of endometrial tumours associated with Lynch syndrome (PETALS): A prospective cross-sectional study.
Ryan NAJ; McMahon R; Tobi S; Snowsill T; Esquibel S; Wallace AJ; Bunstone S; Bowers N; Mosneag IE; Kitson SJ; O'Flynn H; Ramchander NC; Sivalingam VN; Frayling IM; Bolton J; McVey RJ; Evans DG; Crosbie EJ
PLoS Med; 2020 Sep; 17(9):e1003263. PubMed ID: 32941469
[TBL] [Abstract][Full Text] [Related]
10. Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study.
Goodfellow PJ; Billingsley CC; Lankes HA; Ali S; Cohn DE; Broaddus RJ; Ramirez N; Pritchard CC; Hampel H; Chassen AS; Simmons LV; Schmidt AP; Gao F; Brinton LA; Backes F; Landrum LM; Geller MA; DiSilvestro PA; Pearl ML; Lele SB; Powell MA; Zaino RJ; Mutch D
J Clin Oncol; 2015 Dec; 33(36):4301-8. PubMed ID: 26552419
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic Comparison of Lynch Syndrome-associated and "Lynch-like" Endometrial Carcinomas Identified on Universal Screening Using Mismatch Repair Protein Immunohistochemistry.
Mills AM; Sloan EA; Thomas M; Modesitt SC; Stoler MH; Atkins KA; Moskaluk CA
Am J Surg Pathol; 2016 Feb; 40(2):155-65. PubMed ID: 26523542
[TBL] [Abstract][Full Text] [Related]
12. The Role of PD-1 Checkpoint Inhibition in Gynecologic Malignancies.
Garcia C; Ring KL
Curr Treat Options Oncol; 2018 Nov; 19(12):70. PubMed ID: 30397772
[TBL] [Abstract][Full Text] [Related]
13. Lynch Syndrome: Female Genital Tract Cancer Diagnosis and Screening.
Mills AM; Longacre TA
Surg Pathol Clin; 2016 Jun; 9(2):201-14. PubMed ID: 27241104
[TBL] [Abstract][Full Text] [Related]
14. Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer.
Ramchander NC; Ryan NAJ; Walker TDJ; Harries L; Bolton J; Bosse T; Evans DG; Crosbie EJ
Front Immunol; 2019; 10():3023. PubMed ID: 31998307
[TBL] [Abstract][Full Text] [Related]
15. Discordant loss of mismatch repair proteins in advanced endometrial endometrioid carcinoma compared to paired primary uterine tumors.
Ta RM; Hecht JL; Lin DI
Gynecol Oncol; 2018 Dec; 151(3):401-406. PubMed ID: 30340772
[TBL] [Abstract][Full Text] [Related]
16. Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger.
Jensen KC; Mariappan MR; Putcha GV; Husain A; Chun N; Ford JM; Schrijver I; Longacre TA
Am J Surg Pathol; 2008 Jul; 32(7):1029-37. PubMed ID: 18469706
[TBL] [Abstract][Full Text] [Related]
17. Consequences of universal MSI/IHC in screening ENDOMETRIAL cancer patients for Lynch syndrome.
Batte BA; Bruegl AS; Daniels MS; Ring KL; Dempsey KM; Djordjevic B; Luthra R; Fellman BM; Lu KH; Broaddus RR
Gynecol Oncol; 2014 Aug; 134(2):319-25. PubMed ID: 24933100
[TBL] [Abstract][Full Text] [Related]
18. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome.
Rabban JT; Calkins SM; Karnezis AN; Grenert JP; Blanco A; Crawford B; Chen LM
Am J Surg Pathol; 2014 Jun; 38(6):793-800. PubMed ID: 24503759
[TBL] [Abstract][Full Text] [Related]
19. Utility of MLH1 methylation analysis in the clinical evaluation of Lynch Syndrome in women with endometrial cancer.
Bruegl AS; Djordjevic B; Urbauer DL; Westin SN; Soliman PT; Lu KH; Luthra R; Broaddus RR
Curr Pharm Des; 2014; 20(11):1655-63. PubMed ID: 23888949
[TBL] [Abstract][Full Text] [Related]
20. Anti-programmed Death-1 Immunotherapy for Endometrial Cancer with Microsatellite Instability-High Tumors.
Sobecki-Rausch J; Barroilhet L
Curr Treat Options Oncol; 2019 Nov; 20(11):83. PubMed ID: 31754884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
